Pamidronate: Pamidronate is reimbursed only for multiple myeloma and bone metastases associated with breast cancer. Requests for reimbursement for other indications should be directed to Pharmacare for consideration under the special authority process.

Vinorelbine: Effective 01 January 2001, vinorelbine no longer requires undesignated indication approval for more than 6 cycles in metastatic breast cancer.

Susan O’Reilly, MB, FRCPC
Provincial Systemic Program Leader

The current Benefit Drug List is available on the Communities Oncology Network website at http://bccancer.com/providerhome.cfm

PEC PROPOSALS
The following systemic therapy proposals were submitted to the Priorities and Evaluation Committee (PEC) for consideration as new programs. These treatments are not reimbursed at this time unless undesignated indication approval is obtained prior to use.

Breast
- adjuvant CEF (cyclophosphamide, epirubicin, fluorouracil) for locally advanced breast cancer
- exemestane as 2nd or 3rd line hormonal treatment for postmenopausal metastatic breast cancer

Gastrointestinal
- adjuvant combined modality treatment of gastric cancer with chemotherapy (fluorouracil and leucovorin) and radiation
- capcitabine or raltitrexed as an alternative for 1st line treatment of metastatic colorectal cancer

Genitourinary
- gemcitabine and cisplatin for advanced transitional cell carcinoma of the urothelium
Leukemia
- anagrelide as 2nd line treatment for thrombocytosis associated with myeloproliferative disorders

Lymphoma
- CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) plus rituximab as standard treatment for diffuse large B-cell lymphoma

Melanoma
- adjuvant high dose interferon for T4, N1 or resected recurrent N+ malignant melanoma
- temozolomide as 1st or 2nd line treatment for metastatic malignant melanoma

**PROTOCOL UPDATE**

Protocol codes for treatments requiring “Undesignated Indication” approval prior to use are prefixed with the letter U.

- **INDEX to BCCA Protocol Summaries** revised monthly (includes tumour group, protocol code, indication, drugs, last revision date and version)
- **BRAJTAM** revised (tests, precautions): Adjuvant therapy for breast cancer using tamoxifen.
- **BRAVANAS** revised (eligibility): Palliative therapy for metastatic breast cancer using anastrozole.
- **BRAVCAP** revised (treatment, hand-foot grading, renal dysfunction, warfarin monitoring): Palliative therapy for metastatic breast cancer using capecitabine.
- **BRAVLET** revised (eligibility): Palliative therapy for metastatic breast cancer using letrozole.
- **BRAVNAV** revised (eligibility, treatment cycles): Palliative therapy for metastatic breast cancer using vinorelbine.
- **BRAVTAM** revised (tests, precautions): Palliative therapy for metastatic breast cancer using tamoxifen.
- **GOOVCATR** new: Second line treatment using paclitaxel and carboplatin for epithelial ovarian cancer relapsing after primary treatment.
- **GUBEP** revised (tests, stat holiday/weekend scheduling, references): Bleomycin, etoposide and cisplatin for nonseminoma germ cell tumours.
- **GUEP** revised (tests, stat holiday/weekend scheduling, references): Etoposide and cisplatin for germ cell tumours.
- **MYPAM** revised (tests): Treatment of multiple myeloma with pamidronate.

**CANCER MANAGEMENT MANUAL**
The Cancer Management Manual is available on BCCA website [http://www.bccancer.bc.ca/cmm/](http://www.bccancer.bc.ca/cmm/)

**DRUG UPDATE**

**Capecitabine and Renal Dysfunction**

The capecitabine product monograph currently includes a statement that capecitabine had not been studied in severe renal dysfunction. However, the U.S. manufacturer recently issued a warning regarding renal impairment with capecitabine as follows:

**Severe renal dysfunction (CrCl <30 mL/min)**
- Capecitabine is contraindicated. These patients had a high rate of grade 3-4 adverse events and should not be treated.

**Moderate renal dysfunction (CrCl 30-50 mL/min)**
- Dose reduction is required. These patients also had a high rate of grade 3-4 adverse events and should be given 75% doses.

**Mild renal dysfunction (CrCl >50 mL/min)**
- Full doses can be used. These patients had slightly more adverse events and withdrawals but can be given 100% doses.

**BRAVCAP**, the protocol summary for metastatic breast cancer using capecitabine, was revised to reflect these recommendations.

Robin O'Brien, PharmD, BCOP
BCCA Drug Information Specialist
NURSING PRACTICE TIPS

Assessing & Managing Venous Irritation
Associated with Vinorelbine

Vinorelbine was developed to treat a wide variety of cancer tumours. Unfortunately, venous irritation such as injection site reactions, local reactions or superficial phlebitis can occur with administration of this drug. Patients receiving vinorelbine may experience symptoms including erythema, pain at the injection site, vein discolouration, and tenderness along the vein.

A nursing research study done in 1995 compared 2 infusion times: 6-10 minutes versus 20-30 minutes. This was to see if a longer infusion time might decrease the above noted symptoms. As noted by the authors, a potential confounding factor in this study was that the concentration of drug in the solution was not controlled; therefore, different amounts of solution were given at each rate. However, they also noted that if a decreased concentration would be expected to cause less venous irritation, then the incidence should have decreased when vinorelbine was mixed with the most solution (100 mL). This did not occur.

The study supported the manufacturer’s recommendation to administer vinorelbine as a 6–10 minute infusion to reduce vein irritation. However, it is also interesting to note that all patients in the study received 100 mL of fluid before the vinorelbine and 400 mL after. Also, it is interesting to note that none of the doses were given IV push through a side arm.

If you want to read more about this study, it can be found in Oncology Nursing Forum 1995; 22:707-710.

Linda Yearwood, MSN RN
Chair, Nursing Practice Council

COMMUNITIES ONCOLOGY NETWORK

National Community Cancer Conference
And Partners in Cancer Care 2000

News, reports and results of the conferences held on May 13-14, 2000 and November 23, 2000 are available on the Communities Oncology Network website at [http://bccancer.com/conferences.cfm](http://bccancer.com/conferences.cfm) Of particular interest is the interpretation of the relevance and performance questionnaire from the 4th National Community Cancer Conference. Delegates were asked to assess each of 41 statements that arose from the conference deliberations. The aim was to identify statements relevant to the successful delivery of quality cancer care and to identify where system performance was low. It is expected that those responsible for planning and delivering cancer services will place these community cancer issues high on their provincial agendas.

EDITORIAL REVIEW BOARD

Robin O'Brien, PharmD (Acting Editor)
Sharon Allan, MD
Sandi Broughton, BAEcon, MSc
Jack Chritchley, MD
Linda Yearwood, MSN
Lynne Nakashima, PharmD
David Noble, BSc, BLS
Lynn Stevenson, RN
Kelly Uyeno, CGA

Gigi Concon (Secretary)
### REGIONAL CANCER CENTRE ACCESS

<table>
<thead>
<tr>
<th>BULLETIN UPDATES</th>
<th>LOCATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protocol Summaries</td>
<td>H:\everyone\systemic\chemo\Protocol&quot;tumour site&quot;</td>
</tr>
<tr>
<td>BRAJTAM</td>
<td>BRAVTAM</td>
</tr>
<tr>
<td>BRAVANAS</td>
<td>GOOVCATR</td>
</tr>
<tr>
<td>BRAVCAP</td>
<td>GUBEP</td>
</tr>
<tr>
<td>BRAVLET</td>
<td>GUEP</td>
</tr>
<tr>
<td>BRAVNAV</td>
<td>MYPAM</td>
</tr>
<tr>
<td>Index of Protocol Summaries</td>
<td>Index_NT or Index_W6</td>
</tr>
<tr>
<td>Reimbursement</td>
<td>H:\everyone\systemic\chemo\Reimburs</td>
</tr>
<tr>
<td>Benefit Drug List (01 January 2001)</td>
<td>BenefitList.doc</td>
</tr>
<tr>
<td>Class 2 Form (01 January 2001)</td>
<td>Class2.doc</td>
</tr>
<tr>
<td>Systemic Therapy Update Index</td>
<td>Jan-Dec_NT.doc</td>
</tr>
</tbody>
</table>

For easy access, double-click your systemic chemo icon.

We appreciate your comments. Write us at bulletin@bccancer.bc.ca
BCCA SYSTEMIC THERAPY UPDATE FAX REQUEST FORM

I WOULD PREFER TO RECEIVE THIS INFORMATION VIA:

- E-mail (Word 6.0)
- Fax

Please ☐ Fax-Back information below:

- All items
- Protocol Summaries:
  - BRAJTAM
  - BRAVANAS
  - BRAVCAP
  - BRAVLET
  - BRAVNAV
- Benefit Drug List (01 January 2001)
- Class 2 Form (01 January 2001)
- Jan-Dec 2000

TO SUBSCRIBE: FAX OR EMAIL YOUR REQUEST OR CALL @ 877-6098 LOCAL 2247
FOR URGENT REQUESTS PLEASE CALL (604) 877-6098 LOCAL 2247
OR TOLL-FREE IN BC 1-800-663-3333 LOCAL 2247

PLEASE FEEL FREE TO MAKE COPIES FOR YOUR COLLEAGUES